Kymera Therapeutics, Inc. (KYMR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Kymera Therapeutics ( (KYMR)) just unveiled an update. On December 9, 2025, Kymera Therapeutics announced an underwritten public offering of 7,000,000 shares of its common stock at $86.00 per share, ...

Hawaii News Now spoke to Robert Cazimero at the opening of Ke Kilo Lani, an exhibit that showcases his life and legacy as a kumu hula and entertainer. Sen. Glenn Wakai, D, represents District 15: ...

Shares of Kymera Therapeutics, which gained 41% in the day's regular session, were trading lower in the after-hours session, following news the company commenced an underwritten public offering of ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

WATERTOWN, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...

Kymera Therapeutics, Inc. reported robust Phase 1b results for KT-621, showing deep STAT6 degradation and strong clinical efficacy in atopic dermatitis. KT-621 demonstrated a favorable safety profile, ...

Kymera Therapeutics, Inc. (NASDAQ: KYMR) on Monday released clinical results from the BroADen Phase 1b atopic dermatitis (AD) clinical trial of KT-621, its oral STAT6 degrader medicine. STAT6 ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Kymera Therapeutics reported on Monday that, for the second time this year, it has ...